We have studied the relative contributions of monomeric (m-) and polymeric IgA (p-IgA) and of IgA1 and IgA2 to total serum IgA in healthy adults and patients with liver disease (LD) or with other diseases and high serum IgA. Serum concentration of total secretory component (SC) was also determined. In addition, fractional catabolic rates (FCR) and synthetic rates for both m-and p-IgA were measured in nine controls and nine cirrhotics. Our results support four main conclusions: (a) In healthy adults, intravascular p-IgA contributes to only 4-22% (mean 12%) of serum IgA, because its FCR and synthetic rate are approximately two times higher and four times smaller, respectively, than those of intravascular m-IgA. (b) in LD, biliary obstruction does not result in a significant increase in serum p-IgA unlike in rats and rabbits, indicating that in humans the SC-dependent biliary transport of p-IgA plays a much less significant role in selective removal of p-IgA from plasma than in rats and rabbits. (c) In contrast to biliary obstruction, parenchymal LD results in a significant and preferential increase in serum p-IgA, which in cirrhotics correlates with a selective reduction of the pIgA-FCR. This supports a role for the human liver in selective removal of p-IgA from plasma, but another mechanism than the SC-dependent biliary transport should be considered. 
INTRODUCTION
Human IgA occurs in both monomeric (m-IgA)' and polymeric J-chain containing (p-IgA) forms (1, 2) , and comprises two subclasses, IgAl and IgA2 (3) (4) (5) . In normal individuals, p-IgA bound to secretory component (SC) predominates in secretions, whereas in serum 80-90% of IgA are monomeric and most of p-IgA is devoid of SC (1, 2) . Secretions and serum also differ by their proportion of subclasses, with -40% of IgA2 in secretions vs. 20% in serum (6, 7) . SC is an epithelial cell glycoprotein that acts as a membrane receptor for pIgA and IgM at the basolateral surface of the mucosal epithelial cells. It allows the vesicular transcytoplasmic transport of p-IgA and IgM into secretions (8, 9) .
Increased concentrations of IgA in serum occur in various diseases (1, 2) but little is known on the size and subclass of IgA involved in these elevations. In cirrhosis, a preferential increase in the proportion of ' Abbreviations used in this paper: A (12) (13) (14) . Some experimental (15) and clinical evidence (16, 17) suggests that p-IgA may be directly involved in tissue injury in some diseases. Changes in subclass proportions in pathological sera have not been studied but there are conflicting data about the IgA subclass deposits in Berger's disease (13, 18, 19) .
Minute amounts of SC occur in serum (20) , always bound to p-IgA and/or IgM (21, 22) with virtually undetectable free SC unlike in secretions (21, 22) . Although p-IgA, IgA2, and SC in serum have been considered as possible indices of mucosal events, it is not known whether a positive correlation between these three serum parameters occurs in disease.
It seemed likely that differences in tissue origins and metabolic fate of serum IgA in various diseases would be associated with distinct patterns regarding m-IgA, p-IgA, IgAl, IgA2, and SC in serum. We therefore undertook a comparative study of these parameters in some systemic, mucosal, liver, and kidney diseases with elevated total serum IgA. We also compared the metabolic properties of m-and p-IgA in normal individuals and in patients with liver diseases (LD) to assess further the role of the liver in the metabolism of circulating IgA.
METHODS
Patients and controls. We analyzed the sera of 204 caucasian adults not submitted to any immunosuppressive therapy. Controls (n = 34) were clinically healthy volunteers with a mean age of 41 yr (24 to 68 yr). Four main groups of patients were studied. (a) LD were classified as previously described (23) and included (i) chronic active LD (CALD, n = 34; hepatitis B antigen positive, n = 14) comprising chronic active hepatitis (n = 7) and postnecrotic cirrhosis (n = 27); (ii) alcoholic cirrhosis (Al C, n = 37); (iii) primary biliary cirrhosis (PBC, n = 13); (iv) tumoral complete extrahepatic biliary obstruction (B Obst, n = 14) demonstrated by retrograde endoscopic-or transhepatic-cholangiography; (v) acute hepatitis (A Hep, n = 13) with submassive or massive necrosis of the liver in five cases. (b) Connective tissue diseases (n = 30) comprised definite or classical rheumatoid arthritis (RA, n = 7), systemic lupus erythematosus fulfilling four or more acute RA criteria (SLE, n = 13) and primary Sicca syndrome (Sicca, n = 10) associated with systemic symptomatology as described previously (24 (25) . Total SC in serum was measured by the competition radioimmunoassay previously described (26) but using plastic beads rather than cups as solid phase. This assay measures all forms of SC in serum, namely SC bound to pIgA and IgM, free SC being virtually absent in all sera (21, 22) . The concentrations of total SC were expressed in equivalents of IIS sIgA, which was the standard used.
Size distribution of IgA in serum. Sera were divided in 31 fractions of 0.4 ml, after sucrose density gradient ultracentrifugation (SDGU) during 16 h at 38,000 rpm (W2t = 9.11 X 10") on isokinetic (5-21%) gradients in a SW 41 Ti Beckman rotor (Beckman Instruments, Inc., Fullerton, CA), by downward elution under optical density monitoring (27) Results of measurements of the J-chain content in d-IgA compared to a monoclonal d-IgA standard are listed in Table I for three cases with IgA polymers comprising >30% of the total serum IgA. The SDGUprofiles for two of these cases and for one control are shown in Fig. 2 .
The relative contribution of p-IgA to the elevated total IgA in the different disease categories (p-IgA on total IgA regression slope±SD) was the highest in parenchymal LD (0.22±0.01), Sicca (0.23±0.02), Crohn (0.22±0.03), and in IJBP (0.24±0.03). The slopes for these diseases were significantly higher (P < 0.05) than those for SLE and RA (0.15±0.02). The slopes for Berger and B Obst (0.10±0.02, each) were close to that obtained for controls alone (0.11±0.03). These differences are summarized in Fig. 3 .
Survival of injected m-and p-IgA in LD and controls. Results of survivals of I311-m-and '251-p-IgA in cirrhotics compared to controls are listed in Table II. In controls the FCR and synthetic rates of p-IgA were 1.8 times larger (Fig. 4) and 4 times smaller, respectively, than those of m-IgA.
In cirrhotics, serum m-and p-IgA concentrations were increased two and four times, respectively with a significant increase of both intravascular pools. In contrast to controls, the difference between FCR of mand p-IgA was no longer significant because of a selective reduction of the FCR of p-IgA (P < 0.005), with, in three cases, a FCR of p-IgA, in fact, lower than that of m-IgA (Fig. 4) . The reduction of the FCR of p-IgA in cirrhosis correlated significantly (r: 0.74, P < 0.025) with the prothrombin time. In addition in this disease the increase of the intravascular pool of p-IgA correlated (P < 0.005) with both the decrease of the FCR and the increase of the synthetic rate of p-IgA (Fig. 5) , indicating the contribution of both reduced catabolism and increased synthesis to the high serum p-IgA levels. Such correlation for m-IgA was found only with the synthetic rate but to a less significant degree (P < 0.1).
In NS, P > 0.1.
SC in serum. Very high concentrations of total serum SC were found almost exclusively in patients with LD, particularly those with PBC, B Obst and A Hep. Small, but significant increases were also found in Sicca and RA (Fig. 1) . There was no correlation between p-IgA, IgA2, or total IgA and total SC concentration in any patient group.
Subclass distribution of IgA in serum. Compared Size, Subclass, and Metabolism of Serum IgA (Fig. ID) . In cirrhotics, patients with surgical portacaval shunt had values similar to those in other patients. The increase of IgA2 relative to that of total IgA (regression slope±SD) was the highest in Al C (0.35±0.03) and Crohn's disease (0.29±0.03). The slopes in A Hep (0.22±0.02), Berger (0.20±0.02), IJBP (0.17±0.04), CALD (0.17±0.02) and PBC (0.17±0.02), were similar, close to that in controls alone (0.22±0.05). The slope value in Al C was significantly greater than that in each other LD (P < 0.05), and that in Crohn's disease greater than that in IJBP (P < 0.05). However, in connective tissue diseases, slopes (SLE, Sicca, and RA, each 0.09±0.02) pointed to a marked shift (P < 0.001 compared with any other disease category) of the subclass distribution to IgAl when total IgA increased. These differences are summarized in Fig. 3 (33) at similar concentrations as in other mammals (2) , but large additional amounts of m-IgA, not found in most mammals (34) make it the minor component of IgA in human serum. The higher proportions of plasma cells staining for p-IgA (35, 36) or for IgA2 (37) in mucosae than in bone marrow (35, 38) , and the higher proportions of p-IgA (1, 2) or of IgA2 (6, 7) in secretions than in serum, led some authors to regard serum p-IgA and/or IgA2 as being mainly of mucosal origin (2, 10, 13) . In contrast, mIgA and IgAl in serum are likely to originate predominantly from bone marrow (39) where IgAl plasmacytes predominate and are the largest producers of m-IgA in vitro (40) . However, when in vitro spontaneous secretion of IgA from cells is assessed, not only cells from lamina propria but also cells from peripheral lymph nodes and blood produce similar amounts with approximately equal proportions of m-and p-IgA (40) . While in normal young infants and IgA deficient adults the size and the subclass distribution of IgA in serum vary independently (41) , such data in disease are not available.
Tomasi and Grey (1) first reported an increased proportion of serum p-IgA in advanced LD. Since then variable increases of p-IgA have been reported in Al C and also Berger's disease (10) (11) (12) (13) (14) . The differences in the proportion of serum p-IgA reported in both patients and control populations are probably related to the methods and standards used for assaying IgA and to the failure to take into account the influence of the size of IgA on its immunoassays. These factors have been extensively analyzed by our laboratory and reported elsewhere (25, 27, 28) .
The present results confirm that elevations of total serum IgA may be found in a wide variety of diseases (Fig. 1A) . They demonstrate that such elevations can be accompanied either by a similar elevation of both m-and p-IgA (Berger's disease and B Obst) or by a more selective increase in p-IgA as particularly in Sicca, intestinal diseases and parenchymal LD (Fig.  1B, Fib. 3) . That the increase in p-IgA was not due to detection of m-IgA present in immune complexes was confirmed by the stability at pH 3 and the appropriate J-chain content of the high molecular weight IgA.
Analysis of subclass distributions showed that an elevation of total serum IgA was accompanied by a preferential increase of IgAl in connective tissue diseases and to a lesser extent in Berger's disease and CALD (Fig. iD) . Although a statistically significant preferential increase in serum IgA2 was not demonstrated in any group compared to controls, a trend toward a shift to IgA2 was evident in Al C and Crohn's disease when compared with other diseases with elevated total serum IgA (Fig. 3) .
In healthy controls our results show a 1.8 times greater FCR for p-IgA than for m-IgA, but also a higher synthetic rate for the m-than for the p-IgA that reach the intravascular space. We think that the true p-IgA synthetic rate must be much larger than that reported here due to those molecules that never enter the circulating pool because of immediate local excretion at secretory sites. Both these differences in catabolism and synthetic rates explain the lower concentrations of p-IgA than of m-IgA in serum of normal individuals.
In B Obst, there was no increase in serum p-IgA and, in the single patient studied, FCR of m-and pIgA were similar to mean FCR values in controls. We recently showed a selective plasma-to-bile transport of p-IgA in humans (29) . However, we and others (29, 42) have shown that this transport is quantitatively much less important in humans than in rats and rabbits in which a major SC-dependent transhepatocyte transport of p-IgA occurs (43) (44) (45) . Our present lack of serum p-IgA increase in human B Obst, unlike in rats and rabbits in which B Obst results in a 10 times (or larger) increase in serum p-IgA (45, 46) , is thus another argument for major species differences in hepatic transport of p-IgA into bile. It is likely that these species differences reflect differences in tissue distribution of SC in the liver: in human liver, SC was detected immunohistochemically only in and on bile duct cells (47, 48),2 unlike its clearcut demonstration in and on rat and rabbit hepatocytes (49) (50) (51) . Accordingly, the SC-dependent biliary transport of p-IgA in humans is probably restricted to bile duct cells. Our present data on B Obst as well as the previous isotopic studies (29, 42) indicate that this bile duct cell transport plays little role in human plasma p-IgA removal.
Our results in parenchymal LD, in contrast to those in B Obst, show a significant and preferential increase in serum p-IgA. In cirrhotics this preferential increase correlated with a selective reduction of the FCR of pIgA. This reduced p-IgA-FCR contrasts with the independence between serum IgA concentrations and IgA-FCR previously reported in other diseases (52) (53) (54) (55) , and with the reported increased IgG-FCR in cirrhosis (56) . This reduced p-IgA FCR cannot be explained by a reduced transport of serum p-IgA in various secretions since in a secretion such as saliva, -98% of p-IgA derive from local production and are independent from serum p-IgA (29) . The changes in circulating p-IgA concentrations and FCR found in parenchymal LD but not in B Obst, suggest that the human liver may play a role in the selective removal of plasma p-IgA, but by another mechanism than the SCdependent bile duct cell transport into bile. Such a different, SC-independent mechanism would agree with the reported affinity of human hepatocytes for p-IgA but not for m-IgA, independently of the presence of SC on the hepatocyte (48) . The existence and nature of another putative receptor for p-IgA than SC on the human hepatocyte require further study.
Total SC in serum was increased almost specifically in LD with similar values as those previously reported (23, 57, 58) . The present data clearly show the lack of correlation between serum p-IgA and SC-concentrations in contrast to previous suggestions (11) . The independence between these two serum parameters is well illustrated in B Obst, where very high serum SC concurred with normal serum p-IgA; and inversely in intestinal disease where high serum p-IgA concurred with virtually normal serum SC.
We have recently shown that SC in LD sera is not detectable in free form and is present bound to both p-IgA and IgM in proportion related to the serum pIgA/IgM molar ratio (21 
